Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation [PDF]
Frontiers in Oncology, 2023 Ribociclib, a cyclin-dependent kinase 4/6 inhibitor, is a novel targeted therapy for advanced-stage breast cancer. Although ribociclib-induced cutaneous side effects have been previously noted, they have not been well documented.
Jyun-Yan Jhan +6 more
doaj +2 more sources
BMC CancerBackground CDK4/6 inhibitors are primarily used to treat hormone-positive HER-2 negative (HR+/ HER2-) metastatic breast cancer. Although ribociclib is generally well-tolerated, there is limited real-world data on hepatotoxicity associated with its use ...
Onur Baş +11 more
doaj +2 more sources
Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports [PDF]
Frontiers in OncologyThe most frequently used standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer patients consists of a CDK4/6 inhibitor (abemaciclib, ribociclib, or palbociclib) combined ...
Tamara Martos +6 more
doaj +2 more sources
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy [PDF]
npj Breast CancerIn this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial.
Tomás Pascual +20 more
doaj +4 more sources
Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer
Current OncologyBackground: Clinical trials in metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor-2 (HER2)-negative patients have shown that cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors both increase response rates and provide survival
Tugay Avci +3 more
doaj +3 more sources
Delayed-onset vitiligo in metastatic HR+/HER2– breast cancer during long-term ribociclib therapy.
European Journal of Case Reports in Internal MedicineVitiligo is a rare cutaneous adverse event associated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. We report a 56-year-old woman with de novo metastatic HR+/HER2– breast cancer who developed vitiligo several years into long-term ribociclib ...
Elias Tayar, Dhatri Kodali
doaj +2 more sources
Stevens-Johnson syndrome in breast cancer patient treated with ribociclib [PDF]
, 2023 Introduction. Ribociclib is a cyclin-dependent kinase (CDK) inhibitor, widely used in patients with different types of cancer. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe immunologic skin reactions that lead to ...
Kowalczyk, Adam; Department of Oncology with Daily Unit, Tadeusz Koszarowski Cancer Center in Opole, Poland +1 more
core +1 more source
Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer. [PDF]
Cancer MedABSTRACT Background Adjuvant CDK4/6 inhibitors improve outcomes in hormone receptor‐positive, HER2‐negative (HR+/HER2−) early breast cancer, yet some patients still experience recurrence. Early relapse in particular is associated with poor prognosis, but the timing and patterns of recurrence following this treatment remain undefined, limiting further ...
Chen H +6 more
europepmc +2 more sources
Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells [PDF]
, 2022 Mitotane is the only approved drug for treating adrenocortical carcinoma (ACC). The regimen added to mitotane is chemotherapy with etoposide, doxorubicin, and cisplatin.
Laganà, Marta +13 more
core +2 more sources